AnswersPublished22 sources
How BioInnovation Institute Is Funding 17 Research-Based Startups
BioInnovation Institute (BII) has selected 17 research based startups for €9.52 million in convertible loans—€560,000 each—plus access to its innovation platform and support network. A Novo Nordisk Foundation funding frame of up to DKK 5.5 billion (€736 million) for 2026–35 is intended to expand BII into new fields...
Published byEdited with GPT-5.6 TerraImages generated with GPT Image 2
Research answer
Key takeaways
- BioInnovation Institute (BII) has selected 17 research based startups for €9.52 million in convertible loans—€560,000 each—plus access to its innovation platform and support network.
- A Novo Nordisk Foundation funding frame of up to DKK 5.5 billion (€736 million) for 2026–35 is intended to expand BII into new fields and geographies; reporting says BII aims to grow annual startup support from roughl...
- The supplied evidence confirms the 17 company cohort and its broad technology range, but does not provide a verified roster of all company names and technologies.
AI Prompt
openai.comCreate a landscape editorial hero image for this Studio Global article: How is Denmark’s BioInnovation Institute supporting 17 research-based startups through €9.52 million in €560,000 convertible loans, Copenhag. Article summary: BII is pairing non-dilutive-style early-stage infrastructure and acceleration with convertible financing: the 17 selected research-based companies receive €560,000 each, totalling €9.52 million, under its Venture Program. Topic tags: general, general web, user generated. Style: premium digital editorial illustration, source-backed research mood, clean composition, high detail, modern web publication hero. Use reference image context only for broad subject, composition, and topical grounding; do not copy the exact image. Avoid: logos, brand marks, copyrighted characters, real person likenesses, fake screenshots, UI text, readable text, watermarks, charts with fa
BII is using a blended early-stage support model: capital that can convert into equity later, paired with practical resources meant to help research teams become fundable companies. Its latest Venture Programme cohort includes 17 research-based startups receiving €560,000 each, for a combined €9.52 million. 1
What the 17 startups receive
The immediate financial component is a convertible loan. Unlike a priced equity financing, this is debt structured to convert under agreed conditions at a later stage, allowing a young company to raise money before setting a definitive valuation. 4
For this cohort, BII says the funding comes with access to its innovation platform and support network. Reporting on the programme describes laboratory facilities, business expertise and an international investor network alongside the loans. 1
14
BII’s wider Venture Lab model helps explain what that support can involve. The 12-month programme is intended to accelerate business development, scientific maturity and team development, with access to BII labs and offices in Copenhagen. 19
25 BII has also described its objective as addressing early technical and commercial risks while building founders’ leadership capacity.
30
Its published 2026 Venture Lab guidelines specify a DKK 4.2 million convertible loan per project, plus potential support grants of up to DKK 420,000 for programme costs and up to DKK 240,000 toward laboratory rent where applicable. Those are programme terms, so individual companies’ available support and costs may differ. 17
Why facilities and networks matter for research spinouts
Research-based companies often need more than money to move from a promising result to a venture that can attract customers, partners or investors. They may still be establishing intellectual property, building a leadership team or defining a credible path to market.
BII’s grant policy frames Venture Lab around those gaps: qualifying very early-stage companies receive a convertible loan, rent support, educational-programme support, help with business-plan development, and introductions to industry and investment stakeholders. 28 Its Copenhagen offering has included office and laboratory facilities, business-development support, mentoring and international networks.
26
That makes the model an accelerator and infrastructure proposition as much as a financing mechanism. The intended outcome is not simply to fund research activity, but to increase a team’s scientific validation, commercial readiness and ability to raise subsequent capital. 25
The €736 million expansion behind the programme
In January 2026, the Novo Nordisk Foundation allocated up to DKK 5.5 billion (€736 million) to BII under a funding frame running from 2026 through 2035. The Foundation says the funding will enable expansion into new strategic areas and geographies while supporting more entrepreneurs and startups in Denmark and Europe. 9
Reporting on the commitment has linked it to an ambition to lift BII’s annual startup support from approximately 20 companies to 30. 4 The expansion is therefore broader than this one 17-company intake: it is meant to give BII more capacity to translate life-science and deep-tech research into companies across Europe.
BII’s stated mission is to accelerate innovation that benefits people and society. Its Venture Lab, Bio Studio and related programmes focus on the difficult transition between research and a validated venture. 9
25
What is known about the selected companies
The evidence supports the existence of the 17-company cohort, the €560,000 loan per company, and its breadth across biotechnology, healthcare, climate technology, AI, photonics and quantum-related hardware. 1
14
The technology themes associated with the cohort reportedly include green hydrogen, women’s health, emissions monitoring, cell therapy, sustainable materials and food, medicines, surgical diagnostics, AI for medical imaging and protein design, education, carbon conversion, metabolic disease, photonic AI hardware, micro- and nanofabrication, and integrated photonics.
However, the provided sources do not contain a complete, independently verifiable list matching every one of the 17 companies to those themes. A definitive company-by-company roster would require BII’s cohort announcement or company-level source material. Keeping that distinction clear matters: broad sector coverage is documented, while the full mapping of company names to specific technologies is not.
What to watch next
The key test for BII’s model will be whether this combination of convertible capital, facilities and commercial support helps teams cross the gap from research-stage work to validated companies capable of securing follow-on funding. BII already offers a subsequent Venture House programme for former Venture Lab companies, including an 18-month programme and a potential €1.3 million convertible loan, showing that its support is intended to extend beyond the earliest phase. 29
For founders, investors and research institutions, the significance of the €736 million commitment is its potential to expand that pathway: more companies supported each year, broader European reach, and greater capacity in life sciences and deep tech. 9
11
Studio Global AI
Continue your research
This page includes a source-backed answer you can continue inside Studio Global.
People also ask
What is the short answer to "How BioInnovation Institute Is Funding 17 Research-Based Startups"?
BioInnovation Institute (BII) has selected 17 research based startups for €9.52 million in convertible loans—€560,000 each—plus access to its innovation platform and support network.
What are the key points to validate first?
BioInnovation Institute (BII) has selected 17 research based startups for €9.52 million in convertible loans—€560,000 each—plus access to its innovation platform and support network. A Novo Nordisk Foundation funding frame of up to DKK 5.5 billion (€736 million) for 2026–35 is intended to expand BII into new fields and geographies; reporting says BII aims to grow annual startup support from roughl...
What should I do next in practice?
The supplied evidence confirms the 17 company cohort and its broad technology range, but does not provide a verified roster of all company names and technologies.